Cel Sci (CVM) Other Non-Current Liabilities (2010 - 2026)
Cel Sci (CVM) posted Other Non-Current Liabilities of $125000.0 for Q1 2026, little changed sequentially from $125000.0 in Q4 2025, and little changed YoY from $125000.0 in Q1 2025.
Cel Sci (CVM) Other Non-Current Liabilities (2010 - 2026) Analysis & Trends
Cel Sci has reported Other Non-Current Liabilities for 16 years, with the latest figure at $125000.0 in Q1 2026.
- Quarterly Other Non-Current Liabilities changed 0.0% year-over-year to $125000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $125000.0 (changed 0.0% YoY) and the FY2025 annual result came in at $125000.0, changed 0.0% from the prior year.
- Other Non-Current Liabilities was little changed at $125000.0 in Q1 2026 per CVM's latest filing, from $125000.0 in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $125000.0 in Q1 2022 and troughed at $125000.0 in Q1 2022.
- A 5-year average of $125000.0 and a median of $125000.0 in 2022 frame the typical range for Other Non-Current Liabilities.
- The widest YoY moves for Other Non-Current Liabilities: up 0.0% in 2022, down 94.52% in 2022.
- Over 5 years, Other Non-Current Liabilities stood at $125000.0 in 2022, then changed by 0.0% to $125000.0 in 2023, then changed by 0.0% to $125000.0 in 2024, then changed by 0.0% to $125000.0 in 2025, then changed by 0.0% to $125000.0 in 2026.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $125000.0, $125000.0, and $125000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Cel Sci | 2.12 Mn | -4.42 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 125,000.00 |
| Dec 31, 2025 | 125,000.00 |
| Sep 30, 2025 | 125,000.00 |
| Jun 30, 2025 | 125,000.00 |
| Mar 31, 2025 | 125,000.00 |
| Dec 31, 2024 | 125,000.00 |
| Sep 30, 2024 | 125,000.00 |
| Jun 30, 2024 | 125,000.00 |
| Mar 31, 2024 | 125,000.00 |
| Dec 31, 2023 | 125,000.00 |
| Sep 30, 2023 | 125,000.00 |
| Jun 30, 2023 | 125,000.00 |
| Mar 31, 2023 | 125,000.00 |
| Dec 31, 2022 | 125,000.00 |
| Sep 30, 2022 | 125,000.00 |
| Jun 30, 2022 | 125,000.00 |
| Mar 31, 2022 | 125,000.00 |
| Dec 31, 2021 | 125,000.00 |
| Sep 30, 2021 | 125,000.00 |
| Jun 30, 2021 | 125,000.00 |